NSAAs
Nonsteroidal antiandrogens (NSAAs) are a class of drugs that inhibit androgen receptor signaling by binding to the receptor and blocking activation by androgens such as testosterone and dihydrotestosterone. Unlike steroidal antiandrogens, NSAAs do not share a steroid backbone. They are used primarily in the treatment of androgen-driven conditions, most notably prostate cancer, where they are employed in combination with androgen deprivation therapy or as part of treatment for metastatic castration-resistant disease.
Mechanistically, NSAAs act as competitive antagonists of the androgen receptor, preventing AR translocation to the nucleus
Representative NSAAs include flutamide, nilutamide, and bicalutamide (early-generation agents) and enzalutamide and apalutamide (later-generation agents). They
Related topics include androgen receptor antagonists and steroidal antiandrogens.